We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ophthotech Corp. | NASDAQ:OPHT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.39 | 1.39 | 1.42 | 0 | 01:00:00 |
- Webcast Available Through Ophthotech Website -
Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech’s website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will be available for 14 days following the presentation.
About Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. For more information, please visit www.ophthotech.com.
Forward-looking Statements
Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.
OPHT-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20190103005007/en/
InvestorsKathy GalanteOphthotech CorporationVice President, Investor Relations and Corporate Communications212-845-8231kathy.galante@ophthotech.com
MediaAlex Van ReesSmithSolve LLC on behalf of Ophthotech Corporation973-442-1555 ext. 111alex.vanrees@smithsolve.com
1 Year OPHTHOTECH CORP. Chart |
1 Month OPHTHOTECH CORP. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions